Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30300
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rat, Dorothea | - |
dc.contributor.author | Schmitt, Ulrich | - |
dc.contributor.author | Tippmann, Frank | - |
dc.contributor.author | DEWACHTER, Ilse | - |
dc.contributor.author | Theunis, Clara | - |
dc.contributor.author | Wieczerzak, Ewa | - |
dc.contributor.author | Postina, Rolf | - |
dc.contributor.author | van Leuven, Fred | - |
dc.contributor.author | Fahrenholz, Falk | - |
dc.contributor.author | Kojro, Elzbieta | - |
dc.date.accessioned | 2020-01-13T13:19:34Z | - |
dc.date.available | 2020-01-13T13:19:34Z | - |
dc.date.issued | 2011 | - |
dc.date.submitted | 2020-01-09T11:41:17Z | - |
dc.identifier.citation | The FASEB journal, 25 (9) , p. 3208 -3218 | - |
dc.identifier.uri | http://hdl.handle.net/1942/30300 | - |
dc.description.abstract | Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective and neurotrophic properties and is a potent α-secretase activator. As PACAP peptides and their specific receptor PAC1 are localized in central nervous system areas affected by Alzheimer's disease (AD), this study aims to examine the role of the natural peptide PACAP as a valuable approach in AD therapy. We investigated the effect of PACAP in the brain of an AD transgenic mouse model. The long-term intranasal daily PACAP application stimulated the nonamyloidogenic processing of amyloid precursor protein (APP) and increased expression of the brain-derived neurotrophic factor and of the antiapoptotic Bcl-2 protein. In addition, it caused a strong reduction of the amyloid β-peptide (Aβ) transporter receptor for advanced glycation end products (RAGE) mRNA level. PACAP, by activation of the somatostatin-neprilysin cascade, also enhanced expression of the Aβ-degrading enzyme neprilysin in the mouse brain. Furthermore, daily PAC1-receptor activation via PACAP resulted in an increased mRNA level of both the PAC1 receptor and its ligand PACAP. Our behavioral studies showed that long-term PACAP treatment of APP[V717I]-transgenic mice improved cognitive function in animals. Thus, nasal application of PACAP was effective, and our results indicate that PACAP could be of therapeutic value in treating AD. | - |
dc.description.sponsorship | The authors thank Dr. C. Haass (Ludwig Maximilians University Munich, Munich, Germany) for providing antibodies and H. Pearson for critically reading the manuscript. The authors also appreciate the technical help of A. Kanarek. This work was supported by a grant from the Alzheimer Forschung Initiative e.V. (Du¨sseldorf, Germany) to E.K and F.F (07807). | - |
dc.language.iso | en | - |
dc.publisher | FEDERATION AMER SOC EXP BIOL | - |
dc.rights | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. | - |
dc.subject.other | PAC1 receptor | - |
dc.subject.other | G-protein-coupled receptor | - |
dc.subject.other | neuroprotection | - |
dc.subject.other | nasal delivery | - |
dc.title | Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 3218 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | 3208 | - |
dc.identifier.volume | 25 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.source.type | Article | - |
dc.identifier.doi | 10.1096/fj.10-180133 | - |
dc.identifier.pmid | 21593432 | - |
dc.identifier.isi | 000294435200033 | - |
dc.identifier.eissn | 1530-6860 | - |
local.provider.type | PubMed | - |
local.uhasselt.uhpub | no | - |
item.fullcitation | Rat, Dorothea; Schmitt, Ulrich; Tippmann, Frank; DEWACHTER, Ilse; Theunis, Clara; Wieczerzak, Ewa; Postina, Rolf; van Leuven, Fred; Fahrenholz, Falk & Kojro, Elzbieta (2011) Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. In: The FASEB journal, 25 (9) , p. 3208 -3218. | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.contributor | Rat, Dorothea | - |
item.contributor | Schmitt, Ulrich | - |
item.contributor | Tippmann, Frank | - |
item.contributor | DEWACHTER, Ilse | - |
item.contributor | Theunis, Clara | - |
item.contributor | Wieczerzak, Ewa | - |
item.contributor | Postina, Rolf | - |
item.contributor | van Leuven, Fred | - |
item.contributor | Fahrenholz, Falk | - |
item.contributor | Kojro, Elzbieta | - |
crisitem.journal.issn | 0892-6638 | - |
crisitem.journal.eissn | 1530-6860 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fj_ 10_180133.pdf | Published version | 548.14 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
83
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
115
checked on Oct 4, 2024
Page view(s)
32
checked on Sep 7, 2022
Download(s)
12
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.